This year will likely prove to be a banner year for new and seasoned corporate life sciences executives looking to change jobs in the life sciences. With the industry continuing to benefit from the fast pace of technological advancements, the growing influx of venture capital, and an expanding global marketplace, 2019 will bring greater demand for the top leaders needed to catapult life sciences companies forward.

Increasing competition for top life sciences executives across interconnected sectors means that accomplished candidates often attract multiple offers from firms operating in biotech, precision medicine, genomics, and medical diagnostics.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It would be a luxury to be part of the group of financially privileged physicians and buy all the information sources we each believe may have importance. I am continuing the shock of penury most of us have lived in. I am at the end of my career. Having cancer interrupt the last few years is more than inconvenient. There is no rehab. There is no reliable insurance for disability even though I
    have owned the contract for my entire career. There is not an attorney who will touch this. But, it is not part of the conversation in this culture. What is part of the conversation is the need for mature clinicians to aid with the development of acumen by our teams of providers. (I am not a provider, nor a 2 year MBA, sic, read fishwrap). I am always glad to help…I can no longer afford to pay for someone else profit.

    I, as a physician, always felt that I worked for patient’s interests,not money.

    May you all be safe and as well as possible.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy